Results 11 to 20 of about 18,037 (235)
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease [PDF]
Frontiers in Pharmacology, 2021 Diabetic kidney disease (DKD) is a major cause of end-stage kidney disease (ESKD) worldwide. Mineralocorticoid receptor (MR) plays an important role in the development of DKD.
Daiji Kawanami +6 more
doaj +3 more sources
Mineralocorticoid Receptor Antagonists [PDF]
International Cardiovascular Forum Journal, 2019 Two mineralocorticoid receptor antagonists, spironolactone and eplerenone, are currently approved by the FDA. Several non-steroid based ligands are in clinical trials for indications including heart failure, hypertension and diabetic kidney disease, and even more structurally distinct chemical series are reported in the literature with preclinical data
Anneli, Nordqvist, Kenneth L, Granberg
+5 more sources
Mineralocorticoid Receptor Antagonists in ESKD [PDF]
Clinical Journal of the American Society of Nephrology, 2020 There is an urgent need for interventions that reduce cardiovascular risks in patients with ESKD. Recently there has been considerable interest in whether blocking the effects of the mineralocorticoid aldosterone could be such an intervention.
Adhish, Agarwal, Alfred K, Cheung
openaire +2 more sources
Thiazides and mineralocorticoid receptor antagonists in chronic kidney disease [PDF]
Romanian Journal of Medical Practice, 2022 The latest treatment guidelines for patients with arterial hypertension continues to indicate as the first line therapy a minimal association between renin-angiotensin system (RAS) blockers and a thiazide-type or a thiazide-like diuretic.
Andrei Niculae +5 more
doaj +1 more source
A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE
Рациональная фармакотерапия в кардиологии, 2015 The role of aldosterone in pathophysiological processes is considered. The effects of the selective antagonist of mineralocorticoid receptor eplerenone are analyzed. The advantages of eplerenone compared with spironolactone are discussed.
B. B. Gegenava, O. M. Drapkina
doaj +3 more sources
Frontiers in Physiology, 2022 Obesity and/or metabolic diseases are frequently associated with chronic kidney disease and several factors associated with obesity may contribute to proteinuria and extracellular matrix production.
Roberto Palacios-Ramirez +10 more
doaj +1 more source
Mineralocorticoid receptor overactivation-induced remodeling of obese adipose tissue [PDF]
Xin yixueObesity is a chronic disease caused by the long-term interaction of multiple environmental factors on a specific genetic background. Among these factors， the overactivation of mineralocorticoid receptors （MR） plays a significant role in adipose tissue ...
WEN Runzhi, WANG Li, ZHAO Naiqian
doaj +1 more source
Eplerenone–A novel Mineralocorticoid receptor antagonist for the clinical application
Environmental Disease, 2022 Aldosterone is produced from the zona glomerulosa of the adrenal cortex in the adrenal gland, which is main mineralocorticoid hormone. Upon binding the mineralocorticoid receptor, it regulates sodium and potassium absorption, secretion, and retention ...
Nan-Nan Wu, Yuan-Yuan Zhang, Dong Zhao
doaj +1 more source
Mineralocorticoid receptor antagonist use following heart failure hospitalization
ESC Heart Failure, 2020 Aims Patients hospitalized for heart failure (HF) are at increased risk for events post‐discharge. Mineralocorticoid receptor antagonists (MRAs) improve the clinical course of patients with HF with reduced ejection fraction.
Jason M. Duran +3 more
doaj +1 more source
The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone. [PDF]
Clin Pharmacokinet, 2023 Finerenone, a selective and nonsteroidal antagonist of the mineralocorticoid receptor, has received regulatory approval with the indication of cardiorenal protection in patients with chronic kidney disease associated with type 2 diabetes. It is rapidly and completely absorbed and undergoes first-pass metabolism in the gut wall and liver resulting in a ...
Heinig R, Eissing T.
europepmc +3 more sources